La cadena de opciones muestra datos clave de las opciones de acciones de Equillium a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Equillium..

Equillium (NASDAQ:EQ) Bolsa, Cadena de Opciones

Equillium

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium Inc

HSBC BANK 16/05/25 WNT

INVESCO EQQQ ACC UCITS ETF

Invesco Russell 1000 Equal Weight ETF

EQT AB

Equity Bancshares, Inc. Class A Common Stock

Equity Bancshares Inc

Mensa Mining Corp

Equity Commonwealth Common Shares of Beneficial Interest

Equity Commonwealth

Equity Commonwealth 6.50% Pfd Conv Shs Ser D

EQUITABLE FINCL CORP by Equitable Financial Corp.

Equitable Financial Corp

EQB Inc

Equitable Holdings Inc

EQUITABLE HOLDINGS ORD

Equitable Holdings, Inc. Depositary Shares

Equitable Holdings, Inc. Depositary Shares, each representing a 1/1,000th interest in a share of Fixed Rate Noncumulative Perpetual Preferred Stock, Series C

Columbia U.S. Equity Income ETF

EQUINITI GROUP PLC ADR by Equiniti Group PLC

Equinix Inc

ALPS Equal Sector Weight ETF

INVSC S&P 500 EQL WEIGT USD UNT ETF

EQ Labs Inc

Simplify Exchange Traded Funds Simplify Market Neutral Equity Long/Short ETF

iShares Trust iShares MSCI Emerging Markets Quality Factor ETF

EQUITY METALS CORPORATION by Equity Metals Corporation

Equity Metals Corp

Equinor ASA

EQUINOX RES LTD by EQUINOX RES LTD

Eqonex Ltd

IVZ NASDAQ-100 SWAP UCITS ETF DIST

INVESCO NSDQ NXT GEN 100 UCT ETF ACC

INVESCO EQQQ NASDAQ 100 UCITS ETF

IVZ NASDAQ-100 SWAP UCITS ETF

Equity Residential Common Shares of Beneficial Interest

Equity Residential

ProShares Equities for Rising Rates ETF

EQRX INC COM

EQRX INC WT EXP

Equus Total Return Inc

EQS Group AG

EQT Corp

Equal Trading Inc

EQM TECHS & ENERGY INC by EQM Technologies & Energy, Inc.

EQM Technologies & Energy Inc

EQUITECH INTL CORP by Equitech Int'l Corp.

Equitech International Corp

Equitrans Midstream Corp PRF PERPETUAL USD - Ser 4/A2

ALTAMIRE GOLD CORP ORD by Altamira Gold Corp

Altamira Gold Corp

LAKE WINN RESOURCES NEW by Lake Winn Resources Corp

Lake Winn Resources Corp

Valued Advisers Trust Kovitz Core Equity ETF

QuadrantProtocol

EQUATORIAL ENERGIA S/ADR by Equatorial Energia S.A.

Equatorial SA

NYLI Engender Equality ETF

E-Qure Corp

EQV Ventures Acquisition Corp. Class A Ordinary Shares

EQV Ventures Acquisition Corp

EQV Ventures Acquisition Corp. Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant

EQV Ventures Acquisition Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share

Invesco S&P 100 Equal Weight ETF

Equinox Gold Corp

Equalizer

Macro Economic Events

News

Econ #s

Economics

Reported Earlier, China Caixin Manufacturing Purchasing Managers Index For October 50.3 Vs. 49.7 Est.; 49.3 Prior

Reported Earlier, Australia Producer Price Index (QoQ) For Q3 0.9% Vs. 0.7% Est.; 1.0% Prior

Reported Earlier, Australia Producer Price Index (YoY) For Q3 3.9% Vs. 4.8% Prior

Reported Earlier, Australia Home Loans (MoM) For September 0.1% Vs. 2.4% (Revised) Prior

During the <a href="https://www.benzinga.com/news/earnings/24/10/41664778/amazon-q3-earnings-highlights-revenue-beat-eps-beat-q4-guidance-new-kindles-significantly-outperfor">third-quarter earnings</a> call, Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) CEO Andy Jassy underscored the company&#8217;s dedication to its in-house silicon development, despite acknowledging a &#8220;deep partnership&#8221; with Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
What Happened: On Thursday, Jassy acknowledged that while Amazon has a strong partnership with Nvidia for GPUs, customers have expressed a need for better price performance for their AI workloads, especially as they scale up.
&#8220;While we have a deep partnership with Nvidia, we&#8217;ve also heard from customers that they want better price performance on their AI workloads,&#8221; he said during his opening comments.
This has led Amazon to invest in its own custom silicon: Trainium for training and Inferentia for inference.
&#8220;The second version of Trainium, Trainium2 is starting to ramp up in the next few weeks and will be very compelling for customers on price performance,&#8221; he stated.
See Also: <a href="https://www.benzinga.com/news/24/10/41663190/openai-rolls-out-chatgpt-search-google-shares-slide?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">OpenAI Rolls Out ChatGPT Search, Google Shares Slide</a>
The Amazon CEO also highlighted that Amazon Web Services experienced a 19.1% year-over-year growth, reaching an annualized run rate of $110 billion.
He cited customer deals with ANZ Banking Group, Booking.com, Capital One, Fast Retailing, Itaú Unibanco, National Australia Bank, Sony, T-Mobile, and Toyota as evidence of AWS&#8217;s continued success.
&#8220;You can look at our partnership with Nvidia called Project Ceiba, where NVIDIA has chosen AWS&#8217;s infrastructure for its R&amp;D supercomputer due in part to AWS&#8217;s leading operational performance and security,&#8221; Jassy said.
Later while responding to a question, Jassy noted AWS&#8217;s strong partnership with Nvidia saying, &#8220;We tend to be their lead partner on most of their new chips.&#8221;
He added, &#8220;We were the first to offer H200s in EC2 instances. And I expect us to have a partnership for a very long time that matters.&#8221;
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Last month, <a href="https://www.benzinga.com/news/24/10/41337034/amazon-strikes-at-nvidias-stronghold-through-databricks-deal-cutting-ai-costs-by-40">Amazon inked a five-year deal</a> with data and AI startup Databricks, which centered around Amazon's Trainium AI chips, offering a less expensive alternative to Nvidia Corp's popular GPUs.
Meanwhile, Amazon announced third-quarter net sales of $158.9 billion, reflecting an 11% increase compared to the previous year. This total surpassed the consensus estimate of $157.2 billion from analysts, according to data<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener"> from Benzinga Pro.</a>
The company reported third-quarter earnings per share of $1.43, exceeding the Street consensus estimate of $1.14.
Price Action: At the time of writing, Amazon shares surged 6.07% to $197.50 in after-hours trading, recovering from a 3.39% drop to $186.19 during the regular trading session.
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41625103/jim-cramer-says-googles-ai-investment-next-year-should-be-fabulous-for-nvidia?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Says Google&#8217;s AI Investment Next Year &#8216;Should Be Fabulous For Nvidia&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Tech

AMZN

NVDA

Andy Jassy Touts 'Deep Partnership' With Nvidia, But Amazon Is Doubling Down On In-House Custom Silicon For Price-Conscious Customers

During Apple Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) <a href="https://www.benzinga.com/news/earnings/24/10/41666494/apple-q4-earnings-revenue-beat-eps-beat-installed-base-hits-new-highs-iphone-sales-rise-as-apple-in">fourth-quarter earnings</a> call, Tim Cook said that the adoption rate of iOS 18.1 has outpaced its predecessor, iOS 17.1, by two-fold.
What Happened: On Thursday, Apple&#8217;s CEO addressed questions about the demand and supply balance for the iPhone 16, which was <a href="https://www.benzinga.com/news/24/09/40780100/apple-intelligence-ready-iphone-16-with-faster-processor-dedicated-camera-button-announced-check-pri">launched in September</a> earlier this year.
During the conversation, Cook refuted the idea that Apple has consistently ended&nbsp;the December quarter with iPhone&nbsp;demand surpassing supply for the past four years.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/10/41607481/apples-refreshes-mac-mini-smaller-form-factor-m4-chip-power-and-carbon-neutral?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Refreshes Mac Mini: Smaller Form Factor, M4 Chip Power, Carbon Neutral</a>
Cook acknowledged pandemic disruptions but assured that the supply constraints for the iPhone 16 Pro and iPhone 16 Pro Max models would be resolved soon.
Cook attributed the high adoption rate of iOS 18.1 to strong interest in the iPhone 16, which was launched just three days before the earnings call. He suggested that the new Apple Intelligence feature is a significant incentive for users to upgrade.
&#8220;If you just look at the first three days, which is all we have obviously from Monday, the 18.1 adoption is twice as fast as the 17.1 adoption was in the year-ago quarter. And so, there&#8217;s definitely interest out there for Apple Intelligence,&#8221; he stated.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Apple announced a fiscal fourth-quarter revenue of $94.9 billion, surpassing analyst projections of $94.56 billion. The company reported adjusted earnings of $1.64 per share for the quarter, exceeding expectations of $1.60 per share.
This marked the seventh consecutive quarter that Apple has outperformed analyst estimates in both revenue and earnings, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Earlier in October it was reported that the <a href="https://www.benzinga.com/government/24/10/41399541/apple-iphone-16-sees-20-sales-surge-in-china-but-ai-absence-prompts-early-price-cuts">iPhone 16 saw a 20% sales surge in China</a>, a crucial market for Apple, despite early price cuts due to the absence of AI.
Apple also set a new sales record for its iPhone during the third quarter of 2024, <a href="https://www.benzinga.com/markets/equities/24/10/41328252/apples-iphone-16-powers-record-sales-in-q3-just-behind-samsung-in-global-market-share-battle">capturing an 18% market share</a>, just behind Samsung.
However, <a href="https://www.benzinga.com/markets/equities/24/10/41350072/iphone-16-sales-banned-in-indonesia-after-apples-investments-obligations-in-asian-giant-fall-sho">Apple faced a setback</a> when the Indonesian government banned the sale of the iPhone 16 due to the company&#8217;s failure to meet its investment commitments in the country.
Price Action: At the time of writing, Apple shares fell 1.86% to $221.71 in after-hours trading, following a 1.82% decline to $225.91 during the regular trading session, according to<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener"> Benzinga Pro data</a>.
Image via Shutterstock
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41611263/alphabet-q3-earnings-highlights-revenue-beat-eps-beat-google-cloud-up-35-momentum-across-the-compan?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Alphabet Q3 Earnings Highlights: Revenue Beat, EPS Beat, Google Cloud Up 35%, &#8216;Momentum Across The Company Is Extraordinary&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

AAPL

Apple Users Hungry For AI: Tim Cook Says 'iOS 18.1 Has Twice The Adoption Rate Of 17.1' — What It Means For iPhone 16

On Thursday, the Cathie Wood-led Ark Invest made significant moves in the market, with prominent trades involving Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) and Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>).
The Tesla Trade: Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) sold a total of 8,384 shares of the Elon Musk-led company. With Tesla&#8217;s closing price at $249.85 on Thursday, the value of this trade amounts to approximately $2.09 million. This move is in line with Ark&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41642374/cathie-wood-shuffles-her-tech-deck-continues-dumping-tesla-and-palantir-stocks-up-on-amd-and-met">recent trend of reducing its Tesla holdings</a>.
Wood&#8217;s ARK Investment Management sees Tesla's driverless <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob">ride-hailing plans as a game-changer</a>, potentially unlocking $11 trillion in revenue by leveraging lower operating costs of electric vehicles. ARK&#8217;s analysis suggests that Tesla&#8217;s robotaxi service could offer rides at a fraction of current ride-hailing and personal vehicle costs, making it a competitive alternative.
The Meta Platforms Trade: Ark Invest&#8217;s Ark Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), ARKK, and ARKW bought a total of 34,076 shares of Meta Platforms. Given Meta&#8217;s closing price of $567.58 on Thursday, the total value of this trade is approximately $19.34 million. This purchase comes after the Mark Zuckerberg-led company&#8217;s third-quarter earnings report, where the company <a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">beat revenue and EPS estimates</a>.
The Palantir Trade: Ark Invest&#8217;s ARKF, ARKK, and ARKW sold a total of 334,767 shares of Palantir Technologies. With Palantir&#8217;s closing price at $41.56 on Thursday, the value of this trade is approximately $13.9 million. This move follows a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41660695/l3harris-and-palantir-collaboration-key-to-future-growth-bofa-upgrades-stock">recent upgrade</a> of L3Harris Technologies, a key collaborator with Palantir, by BofA Securities.
The Block Trade
Ark Invest&#8217;s decision to offload shares of Block Inc. was a notable one. The firm sold 243,549 shares of the Jack Dorsey-led company from its ARKK and ARKW. The value of this trade, based on Block&#8217;s closing price of $72.32 on the same day, amounts to approximately $17.6 million.
The move came on the same day that Block CEO Dorsey <a href="https://www.benzinga.com/news/24/10/41646193/block-ceo-jack-dorsey-announces-another-round-of-layoffs-at-tidal">announced a fresh wave of layoffs</a> at Tidal. In a note to Tidal employees, Dorsey stated the need for the company to function &#8220;like a startup again,&#8221; necessitating a much smaller team across the organization.
Interestingly, the trade also comes at a time when Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), a core focus of Block, has been <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41596516/bitcoin-clips-71-500-as-wall-street-etf-inflows-fuel-bullish-momentum-whats-next">hovering near previously reached all-time highs.</a>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41616239/shytoshi-kusama-touts-shiba-inu-lifetime-gains-of-33774726-we-still-have-far-to-go-and-muc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shytoshi Kusama Touts Shiba Inu Lifetime Gains Of 33774726%: &#8216;We Still Have Far To Go And Much Work To Be Done&#8217;</a> 
Other Key Trades:
<ul>
<li>Ark Invest&#8217;s ARKF and ARKK bought a total of shares of Roku Inc. (ROKU).</li>
<li>Ark Invest&#8217;s ARKK bought shares of Twist Bioscience Corp (TWST). Ark Invest&#8217;s ARKK sold shares of Moderna Inc. (MRNA).</li>
</ul>
Photo Courtesy: Ark Invest
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41644730/shytoshi-kusama-schools-x-user-who-said-shib-will-remain-chump-change-meme-unless-it-can-r?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shytoshi Kusama Schools X User Who Said SHIB Will Remain &#8216;Chump Change Meme&#8217; Unless It Can Rise Above A Penny: &#8216;Those Who Are Wise Give Us Respect&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

Markets

ETFs

$BTC

ARKF

ARKK

ARKW

PLTR

TSLA

Cathie Wood Bets Big On Mark Zuckerberg: Ark Pours $19M Into Meta Shares, Dumps Palantir And Tesla Stock

While discussing Meta Platforms Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) <a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">third-quarter earnings</a> report, financial analyst Jim Cramer made a striking statement about CEO Mark Zuckerberg&#8216;s marketing prowess.
What Happened: On Thursday, during a conversation on CNBC&#8217;s Squawk on the Street, Cramer and Scott Wapner discussed Meta&#8217;s potential for long-term growth.
During this time, Cramer suggested that tech leaders like Zuckerberg operate on a different level, stating, &#8220;These guys think different from you and me.&#8221;
&#8220;They have a view which just says we want to dominate in this area. So we are going to spend a little more than others and we will dominate,&#8221; he added.
Cramer then used Procter &amp; Gamble as an example, stating that if the company wanted to make Tide a global brand, it would need to pay Zuckerberg a significant amount.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41621390/google-just-got-fined-in-russia-and-its-more-than-the-worlds-gdp-20-decillion-for-blocking-media?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Google Just Got Fined In Russia And It&#8217;s More Than The World&#8217;s GDP: $20 Decillion For Blocking Media Content</a>
In return, Zuckerberg could target 1.6 billion potential customers currently deciding between Tide and other brands.
&#8220;He can target them,&#8221; Cramer said, referring to Zuckerberg&#8217;s ability to identify potential customers. &#8220;He knows who is trying to decide. I&#8217;ve never seen anything like it. He has your brain.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">After <a href="https://twitter.com/search?q=%24META&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$META</a> reported earnings for Q3, <a href="https://twitter.com/jimcramer?ref_src=twsrc%5Etfw">@jimcramer</a> and <a href="https://twitter.com/ScottWapnerCNBC?ref_src=twsrc%5Etfw">@ScottWapnerCNBC</a> discuss whether their strategy will sustain long-term growth. &quot;These guys think different from you and me.&quot; <a href="https://t.co/338vlfEEGc">pic.twitter.com/338vlfEEGc</a>
&mdash; Squawk on the Street (@SquawkStreet) <a href="https://twitter.com/SquawkStreet/status/1852093063394365810?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Meta reported third-quarter revenue of $40.59 billion, surpassing analyst expectations of $40.29 billion. Adjusted earnings for the quarter came in at $6.03 per share, exceeding the forecasted $5.25 per share.
Meta projects fourth-quarter revenue between $45 billion and $48 billion, compared to an estimated $46.31 billion. For the full year 2024, expected total expenses are revised to $96 billion to $98 billion, down from previous guidance of $96 billion to $99 billion. 
Despite the positive earnings report, Meta witnessed a drop in stocks during the after-hours trading. However, in his earlier post, Cramer <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41649350/as-microsoft-meta-slide-after-earnings-calls-jim-cramer-says-hyperscalers-are-not-w">dismissed concerns</a> about worsening AI losses, underscoring that the tech giant is thriving with AI advancements.
Price Action: At the time of writing, Meta shares rose 0.14% to $568.40 in after-hours trading, following a 4.09% drop to $567.58 during the regular session, according to<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener"> Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41593651/how-to-unlock-apple-intelligence-on-your-iphone-with-ios-18-1?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">How To Unlock Apple Intelligence On Your iPhone With iOS 18.1</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Jim Cramer Says Mark Zuckerberg Has 'Your Brain' As Meta Pours Billions Into Global Domination Strategy

U.S. stocks turned downward on Thursday, with the Nasdaq Composite dipping around 500 points. The Dow traded down 0.9% to 41,763.46 while the NASDAQ fell 2.76% to 18,095.15. The S&amp;P 500 also fell, dropping, 1.9% to 5,705.45.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
Apple shares closed down 1.82% at $225.91, with an intraday high of $229.83 and a low of $225.37. The 52-week range is $164.08 to $237.49. The iPhone maker reported a fiscal <a href="https://www.benzinga.com/news/earnings/24/10/41666494/apple-q4-earnings-revenue-beat-eps-beat-installed-base-hits-new-highs-iphone-sales-rise-as-apple-in">fourth-quarter revenue</a> of $94.9 billion, beating analyst estimates.
Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
Amazon shares ended the day down 3.39% at $186.19, with an intraday high of $190.6 and a low of $185.23. The 52-week range is $133.85 to $201.2. The online retail giant posted <a href="https://www.benzinga.com/news/earnings/24/10/41664778/amazon-q3-earnings-highlights-revenue-beat-eps-beat-q4-guidance-new-kindles-significantly-outperfor">third-quarter net sales</a> of $158.9 billion, up 11% year-over-year.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41616239/shytoshi-kusama-touts-shiba-inu-lifetime-gains-of-33774726-we-still-have-far-to-go-and-muc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shytoshi Kusama Touts Shiba Inu Lifetime Gains Of 33774726%: &#8216;We Still Have Far To Go And Much Work To Be</a>
Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)
Intel shares closed down 3.50% at $21.52, with an intraday high of $22.25 and a low of $21.47. The 52-week range is $18.51 to $51.28. The chipmaker reported an EPS <a href="https://www.benzinga.com/news/earnings/24/10/41665395/intel-stock-climbs-on-better-than-expected-q3-results-details">loss of 46 cents</a> against an estimate of a loss of two cents.
Peloton Interactive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>)
Peloton shares soared 27.82% to close at $8.5, with an intraday high of $8.92 and a low of $7.67. The 52-week range is $2.7 to $8.92. The fitness company<a href="https://www.benzinga.com/news/earnings/24/10/41657705/peloton-gears-up-for-next-chapter-sales-beat-apple-alum-as-ceo-and-strong-margin-gains"> smashed first-quarter sales estimates</a> and reported a GAAP net loss of $1 million.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla shares ended the day down 2.99% at $249.85, with an intraday high of $259.75 and a low of $249.25. The 52-week range is $138.8 to $273.54. The EV maker remains <a href="https://www.benzinga.com/news/24/10/41646587/tesla-remains-californias-top-ev-choice-even-as-registrations-drop-cybertruck-among-10-best-selling">California&#8217;s top EV choice</a> even as registrations drop.
Prepare for the day&#8217;s trading <a href="Premarket Movers &amp; News">with top premarket movers and news</a> by Benzinga.
Photo Courtesy: Ishant Mishra On Unsplash
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41568577/elon-musk-channels-warren-buffett-as-teslas-stock-booms-after-strong-q3-having-a-publicly-traded?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Channels Warren Buffett As Tesla&#8217;s Stock Booms After Strong Q3: &#8216;Having A Publicly Traded Company Is Like…&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

INTC

PTON

Apple, Amazon, Intel, Peloton, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Former President Donald Trump has responded to billionaire Mark Cuban&#8216;s claim that Trump does not surround himself with strong women, calling Cuban a &#8220;major loser.&#8221;
What Happened: On Thursday, Trump took to X to counter Cuban&#8217;s assertion that he avoids the presence of &#8220;strong, intelligent women.&#8221; Trump&#8217;s post, which was a direct response to Cuban&#8217;s comments on &#8220;The View,&#8221; stated that he is, in fact, surrounded by the &#8220;strongest women in the world,&#8221; including heads of countries. He further criticized Cuban, calling him a &#8220;fool&#8221; and a &#8220;major loser.&#8221;
Trump said, &#8220;He should go back to talk about the person he was forced to support, because I didn't want it, Lyin' Kamala Harris.&#8221;
&#8220;All strong women, and women in general, should be very angry about this weak man's statement,&#8221; said the former president.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Mark Cuban, a really dumb guy, who thinks he's "hot stuff" but he's absolutely nothing, is now out there saying that I don't surround myself with strong women. Actually, he is very wrong, I surround myself with the strongest of women &#8211; With the understanding that ALL women are…
&mdash; Donald J. Trump (@realDonaldTrump) <a href="https://twitter.com/realDonaldTrump/status/1852119259729822180?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban too clarified his comments in an X post. The &#8220;Shark Tank&#8221; fame billionaire emphasized that he wasn't suggesting female Trump supporters lack intelligence or strength, pointing out that many women in his extended family support Trump. He also acknowledged Trump's history of working with strong women, including figures like Elaine Chao, Kellyanne Conway, and Ivanka Trump.
&#8220;He doesn't like to be challenged by them,&#8221; said Cuban. He concluded by saying, &#8220;I stand by my opinion that he does not like being challenged publicly.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Let's clarify something. This is what I said during a conversation about why Nikki Haley was not active in his campaign "Donald Trump, you never see him around strong, intelligent women. Ever. It's just that simple. They're intimidating to him. He doesn't like to be challenged…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1852078484337643864?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41619022/trumps-billionaire-ally-plans-to-join-elon-musks-doge-if-named-treasury-secretary-recommen?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Billionaire Ally Plans To Join Elon Musk&#8217;s DOGE If Named Treasury Secretary, Recommends Elimination Of These Subsidies</a>
Why It Matters: Trump&#8217;s tweet came in response to Cuban&#8217;s remarks on &#8220;The View&#8221; on Thursday, where he accused Trump of avoiding &#8220;strong, intelligent&#8221; women. Cuban, a campaign surrogate for Vice President Kamala Harris, suggested that such women are &#8220;intimidating&#8221; to Trump.
This is not the first time Trump and Cuban have publicly sparred. Earlier this month, Trump launched a <a href="https://www.benzinga.com/news/24/10/41417224/trump-unleashes-scathing-attack-on-former-friend-mark-cuban-after-billionaire-criticizes-ex-presiden">scathing attack</a> on Cuban, calling him a &#8220;weak and pathetic bully&#8221; after Cuban criticized Trump&#8217;s tariff proposals at a Harris campaign rally. Benzinga reported on the feud, noting that the two have had a complex relationship since 2002.
The latest exchange between Trump and Cuban comes less than a week before the 2024 presidential election, where Trump is running against Vice President Kamala Harris. According to a recent poll, Harris <a href="https://www.benzinga.com/news/24/10/41417224/trump-unleashes-scathing-attack-on-former-friend-mark-cuban-after-billionaire-criticizes-ex-presiden">maintains a lead over Trump</a>, but her odds in prediction markets and betting odds have trailed the former president.
Image via Shutterstock
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Mark Cuban Says Trump Avoids 'Strong, Intelligent Women' — Ex-President Fires Back: Just A 'Really Dumb Guy Who Thinks He's Hot Stuff'

An advertisement featuring Julia Roberts has sparked controversy. The ad encourages women to vote for Vice President Kamala Harris, irrespective of their husbands&#8217; political inclinations.
What Happened: The ad, released by the non-profit organization Vote Common Good, has been met with significant backlash from Republicans, reports <a href="https://thehill.com/homenews/campaign/4964265-kamala-harris-ad-julia-roberts/">The Hill</a>. The advertisement subtly touches upon the contentious issue of abortion rights and urges women to exercise their voting rights freely. Some Republicans have equated a wife&#8217;s secret vote for Harris to infidelity.
&#8220;In the one place in America where women still have a right to choose, you can vote any way you want. And no one will ever know,&#8221; says Roberts in the ad.
The voter in the ad featuring Roberts winks when her husband asks if she had made the &#8220;right choice.&#8221;
Among the critics are Fox News host Jesse Watters and GOP member Charlie Kirk, who expressed their disapproval publicly. In response, Doug Pagitt, Executive Director of Vote Common Good, defended the ad, stating that the outrage from certain men fearing disagreement from their wives only proves their point.
Kirk described the advertisement as &#8220;nauseating.&#8221; Former Rep. Liz Cheney (R-Wyo.) responded to Kirk&#8217;s outrage by calling him a &#8220;twit.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Listen to this twit make Donald Trump's closing argument. Women, you know what to do. <a href="https://twitter.com/hashtag/VoteKamala?src=hash&amp;ref_src=twsrc%5Etfw">#VoteKamala</a> <a href="https://t.co/sh4Ogyj4Z5">pic.twitter.com/sh4Ogyj4Z5</a>
&mdash; Liz Cheney (@Liz_Cheney) <a href="https://twitter.com/Liz_Cheney/status/1851963459266625874?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/24/10/41590597/bernie-sanders-explains-why-he-will-vote-for-kamala-harris-even-though-he-disagrees-with-her-stance?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bernie Sanders Explains Why He Will Vote For Kamala Harris Even Though He Disagrees With Her Stance On Is</a>
Why It Matters: This controversy comes in the backdrop of a highly polarized political climate. <a href="https://www.benzinga.com/markets/equities/24/06/39125577/julia-roberts-and-george-clooney-back-joe-biden-in-presidential-race-yet-hollywood-has-largely-h">Earlier this year</a>, Julia Roberts, along with George Clooney, backed Joe Biden in the presidential race. However, many in Hollywood have been hesitant to engage due to the intense polarization.
As the 2024 presidential election nears, the race between former President Donald Trump and Vice President Kamala Harris remains close. <a href="https://www.benzinga.com/general/politics/24/10/41667786/harris-vs-trump-vice-presidents-lead-shrinks-key-demographic-grows-one-week-before-2024-election">Recent polls</a> show Harris maintaining a lead over Trump, although her odds in prediction markets have trailed the former president.
With the election just around the corner, the impact of this controversy on the voting patterns of women remains to be seen.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Conservatives Angry With Julia Roberts Ad Urging Women To Vote For Kamala Harris: 'Nauseating'

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

FGFPP

As blockchain technology continues to enter mainstream financial systems, Markus Kuhnert, founder and CEO of 1iO, has raised concerns about its core principles being overshadowed. 
Ahead of the upcoming <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets </a>event, a BRANDGUARDIAN representative, responding on behalf of Kuhnert, emphasized the potential and challenges of blockchain's growing role in finance.
<h1 class="wp-block-heading">Integrating Blockchain in Finance</h1>
The increasing adoption of blockchain by financial players, including Citi and JPMorgan, could offer advantages such as faster transactions and improved transparency. However, Kuhnert's spokesperson highlighted a key issue: "When blockchain is centrally controlled, it loses its essence and potential."
Blockchain was initially designed to decentralize transactions, removing the need for central authorities. But, as it becomes part of traditional finance, its decentralized nature may be compromised.
<figure class="wp-block-image size-full"><a href="https://benzinga.swoogo.com/digital-assets/6342807"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29171736/905735A6-57D3-4874-9AA1-75D037842DB3-1-3.gif" alt="" class="wp-image-620477" /></a></figure>
<h1 class="wp-block-heading">Bitcoin as a Model</h1>
The spokesperson cited Bitcoin as an example of blockchain's core mission. Unlike blockchain applications within centralized finance, Bitcoin remains under user control, free from centralized oversight. 
&#8220;Bitcoin exemplifies this independence, standing as an asset class under user control, not centralized oversight," the spokesperson explained, adding that integrating blockchain into finance is positive but should not stray from its foundational principles.
<h1 class="wp-block-heading">Ensuring Responsible Adoption</h1>
As the financial industry continues to embrace blockchain, Kuhnert&#8217;s spokesperson insists that preserving decentralization must be a priority. 
"It's crucial to ensure these integrations respect the core principles of decentralization," the spokesperson stated. The push for blockchain's adoption should balance efficiency and transparency with maintaining its original mission of decentralized user control.
The upcoming <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets </a>event will further explore these topics as industry leaders discuss how blockchain can reshape financial systems while remaining true to its purpose.
<hr class="wp-block-separator has-alpha-channel-opacity" />
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities and adoption trends will define the future of this dynamic field.&nbsp;<a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s Future of Digital Assets</a>&nbsp;event in New York City on Nov. 19 will provide industry leaders and investors a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.
Photo by SvetlanaParnikova on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

Events

Exclusives

Interview

Blockchain In Finance: 1iO's Take On Balancing Efficiency And Decentralization

The head-to-head race between former President Donald Trump and Vice President Kamala Harris remained close with less than one week until the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
What Happened: Harris maintains a lead over Trump in many election polls as Election Day nears, but her odds in prediction markets and betting odds have trailed the former president by <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41635149/2024-election-odds-on-polymarket-kalshi-show-trump-will-win-why-they-might-be-wrong">a wide margin.</a>
A new Morning Consult <a href="https://pro.morningconsult.com/trackers/2024-presidential-election-polling?utm_source=briefing&amp;utm_medium=email&amp;utm_campaign=washington_am&amp;utm_content=102924">poll </a>of likely voters shows Harris' lead dropping, continuing a recent string of a lead of six points shrinking.
The new poll shows the following results from voters, with results from<a href="https://www.benzinga.com/general/politics/24/10/41477318/trump-vs-harris-vice-president-holds-slim-lead-losing-momentum-in-key-demographics-favorability-" target="_blank" rel="noreferrer noopener">&nbsp;the Oct. 22 poll&nbsp;</a>in parentheses:
<ul>
<li>Kamala Harris: 50 (50%)</li>
<li>Donald Trump: 47% (46%)</li>
<li>Someone Else: 1% (2%)</li>
<li>Don&#8217;t Know: 2% (2%)</li>
</ul>
The poll also found that 94% of Democrats backed Harris as their top pick, down one percentage point from last week&#8217;s poll. The poll also found 92% of Republicans backed Trump as their top pick, in line with last week&#8217;s poll.
Independent voters selected the following as their head-to-head preference, with the results from the Oct. 22 poll in parentheses:
<ul>
<li>Kamala Harris: 49% (47%)</li>
<li>Donald Trump:&nbsp;43% (43%)</li>
<li>Someone Else:&nbsp;4% (4%)</li>
<li>Don&#8217;t Know:&nbsp;4% (7%)</li>
</ul>
The vice president also has the edge in the 18-34 age voters demographic, leading 54% to 44%. The 10-point lead is up from last week's eight-point advantage for the vice president.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent103124" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It&#8217;s Important: Harris&#8217; lead over Trump dropped to three points, down from a four-point lead in the past two weeks. The lead is down from a six-point lead Harris had several weeks ago.  
After seeing her lead decline in the key Independent and young voter demographics, Harris grew the lead in these two important voter segments with one week until Election Day.
Morning Consult said in the poll that 45% of likely voters said they had heard something positive about Harris, keeping a trend of the vice president having positive net buzz in place. The poll found that 49% of likely voters said they had recently heard something negative about Trump.
The good news for Trump in the poll, along with shrinking Harris' overall lead, is the Republican party being favored on several key election issues. The Republicans were more favored in the poll on items such as the economy, national security and immigration over the Democratic Party. In the poll, the Democratic Party was more favored on health care, climate change and abortion versus the Republican Party.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/10/41589659/trump-vs-harris-state-by-state-2024-election-betting-odds-which-candidate-is-favored-to-wi">Trump Vs. Harris: State-By-State 2024 Election Betting Odds, Which Candidate Is Favored To Win In Your Community?</a></li>
</ul>
Photo: Shutterstock

Harris Vs. Trump: Vice President's Lead Shrinks, Key Demographic Grows One Week Before 2024 Election Day

A legal dispute between the companies behind popular television game shows &#8220;Wheel of Fortune&#8221; and &#8220;Jeopardy!&#8221; <a href="https://www.benzinga.com/quote/SONY">has broken out</a>.
What To Know: Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) and CBS, which is owned by Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>), have worked together on the iconic game shows for years. Sony produces &#8220;Wheel of Fortune&#8221; and &#8220;Jeopardy!&#8221; and CBS oversees the distribution.
Sony on Thursday filed a lawsuit against CBS, claiming the company earned distribution fees from unauthorized deals and has become incapable of properly distributing the shows, according to a Wall Street Journal <a href="https://www.wsj.com/business/media/jeopardy-and-wheel-of-fortune-at-center-of-legal-feud-between-sony-and-cbs-d744b6fc">report</a>.
Sony alleged that CBS has assigned improper value to the shows to serve its own interests, including licensing the shows at prices below market rates and favoring its own shows when setting up distribution deals or selling ads. 
CBS has been in charge of distribution for the game shows since 1999, receiving 35% to 40% commissions on the fees television stations pay to carry the shows. The report indicates that typical distribution commissions are usually closer to 15%. &#8220;Wheel of Fortune&#8221; and &#8220;Jeopardy!&#8221; generate more than $100 million in profits each year, according to a person familiar with the matter.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41666494/apple-q4-earnings-revenue-beat-eps-beat-installed-base-hits-new-highs-iphone-sales-rise-as-apple-in">Apple Q4 Earnings: Revenue Beat, EPS Beat, Installed Base Hits New Highs, iPhone Sales Rise As Apple Intelligence &#8216;Supercharges&#8217; Product Lineup</a>
Sony claimed CBS entered into long-term contract agreements with networks in New Zealand and Australia, which breaches contract terms that prohibit the company from signing deals that span more than two years.
Sony also alleged that layoffs at CBS have negatively impacted the teams that work on the iconic shows. 
"CBS has gutted the teams responsible for fulfilling its contractual obligations, requiring us to step in at our own expense," Sony said in a statement.
Sony reportedly said it&#8217;s seeking damages and plans to try to end its agreement with CBS to pursue alternative distribution and advertising partners. 
Shares of CBS parent Paramount Global were down 0.37% in after-hours, trading at $10.90 at the time of publication Thursday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/10/41633013/sony-adds-new-death-note-game-to-november-ps-plus">Sony Adds New Death Note Game To November PS Plus</a></li>
</ul>
Photos: IMDb

Entertainment

Legal

Media

PARA

PARAA

Sony Group Corporation American Depositary Shares

SONY

Sony Sues CBS, Alleges Breach Of Contract Related To Iconic Game Shows 'Wheel Of Fortune,' 'Jeopardy!'

Business Outlook
Intel's guidance for the fourth quarter of 2024 includes both GAAP and non-GAAP estimates as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Q4 2024</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">GAAP</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Non-GAAP</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$13.3-14.3 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">36.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">39.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax Rate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(50)%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">13%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Earnings (Loss) Per Share Attributable to Intel—Diluted</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$(0.24)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.12</td>
</tr>
</tbody>
</table>
</figure>
Reconciliations between GAAP and non-GAAP financial measures are included below. Actual results may differ materially from Intel's business outlook as a result of, among other things, the factors described under "Forward-Looking Statements" below. The gross margin and EPS outlook are based on the mid-point of the revenue range.

Guidance

Intel Sees Q4 2024 Non-GAAP EPS $0.12 Vs $0.08 Est.; Revenue $13.3B-$14.3B Vs $13.66B Est.

A recent analysis by the Centers for Disease Control and Prevention (CDC) reveals that workers in the food service and hospitality industries are among the highest consumers of <a href="https://www.benzinga.com/markets/cannabis/22/01/25169588/how-cannabis-legalization-is-changing-the-american-workplace">marijuana in the United States. </a>
The study, <a href="https://ajph.aphapublications.org/doi/10.2105/AJPH.2024.307788">published</a> in the American Journal of Public Health, draws from five years of federal health survey data, specifically the CDC's Behavioral Risk Factor Surveillance System (BRFSS) from 2016 to 2020.
<h3 class="wp-block-heading">Key Findings From The Study</h3>
Researchers gathered data from 128,615 individuals across 15 states, including Alaska, Colorado, Florida and Illinois. They discovered significant variations in cannabis use across different industries and occupations.
See Also: <a href="https://www.benzinga.com/markets/cannabis/23/08/33505217/cannabis-use-during-off-hours-not-associated-with-elevated-risk-of-workplace-accidents-finds-new">Cannabis Use During Off-Hours Not Associated With Elevated Risk Of Workplace Accidents, Finds New Study</a>
For instance, about 20.7% of employees in accommodation and food services reported using marijuana and 17.5% in arts, entertainment and recreation field. In contrast, law enforcement showed the lowest prevalence, with only 0.5% of workers reporting recent use.
When examined by occupation, food preparation and serving-related jobs led with 21.9%, followed by roles in arts and media at 17.0%. Interestingly, jobs in education and healthcare showed lower rates, with only 5.7% and 4.7% reporting cannabis use, respectively. Overall, the study found that approximately 10.7% of workers aged 18 and older reported past-month cannabis use.
<h3 class="wp-block-heading">Implications For Workplace Policies</h3>
The researchers noted that the findings can shape future discussions on workplace policies concerning drug use. They pointed out the need for strategies that minimize the risks associated with cannabis consumption, especially in industries prone to high injury rates like construction and forestry. 
"The primary goal for both employers and employees should be to limit the risk of injury while maintaining productivity," the report states.
Despite mixed evidence regarding the relationship between cannabis use and workplace accidents, concerns linger, particularly in safety-sensitive roles. 
"More research is needed to understand factors driving cannabis use in high-risk industries," the authors noted. They also called for clarity on how much cannabis use might affect job performance, stressing that many workers may consume cannabis outside of working hours.
<h3 class="wp-block-heading">Changing Legal Landscape And Workplace Drug Testing</h3>
As cannabis legalization continues to spread across the U.S., employers and policymakers are reevaluating drug testing protocols. Notably, companies like Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and <a href="https://www.benzinga.com/markets/cannabis/24/08/40611728/home-depot-to-end-marijuana-testing-limit-screening-for-most-employees-internal-memo-reveals">Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) have altered their drug screening practices</a>, moving away from pre-employment cannabis testing.
Some states have enacted laws to protect employees from discrimination related to lawful off-duty cannabis use, such as California and <a href="https://www.benzinga.com/markets/cannabis/23/02/31026805/job-seekers-relax-cannabis-use-no-longer-a-barrier-to-employment-in-washington-state">Washington.</a>
In New Jersey, ongoing litigation has emerged over police officers testing positive for THC, revealing conflicts between local governance and state guidelines. Meanwhile, Cleveland Ohio&#8217;s Mayor Justin Bibb announced changes to city job drug testing policies to align with the new cannabis laws.
<h3 class="wp-block-heading">Shifts In Sports And Cannabis Policies</h3>
Professional sports leagues are also revisiting their cannabis policies in response to changing societal views on marijuana. The National Basketball Association (NBA) and Major League Baseball (MLB) have both removed marijuana from their banned substances lists. 
The NCAA followed suit for Division I athletes, and the Ultimate Fighting Championship (UFC) has revised its stance as well.
However, there remains criticism of the World Anti-Doping Agency's ongoing prohibition of cannabis, especially following high-profile cases like that of the world&#8217;s fastest female runner Sha'Carri Richardson who was banned from <a href="https://www.benzinga.com/markets/cannabis/21/07/22025295/the-prohibition-of-cannabis-robbed-shacarri-richardson-but-also-expedited-the-federal-decriminal" target="_blank" rel="noreferrer noopener">competing at the Tokyo Olympics</a> for testing positive for cannabis in 2021.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/02/36896965/wall-street-waves-goodbye-to-weed-testing-how-financial-giants-reshape-job-eligibility-in-the-ca">Wall Street Waves Goodbye To Weed Testing: How Financial Giants Reshape Job Eligibility In The Cannabis Era</a></li>
</ul>
Cover image made with AI.

Cannabis

Gaming

Which Industries Have The Highest Cannabis Consumption At Work? New Data Has Answers

Canaccord Genuity analyst Joseph Vafi maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Buy and raises the price target from $173 to $300.

Price Target

Analyst Ratings

MSTR

Canaccord Genuity Maintains Buy on MicroStrategy, Raises Price Target to $300

Helport AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPAI#NASDAQ">HPAI</a>) reported quarterly earnings of $47.24 thousand per share. This is a 53.06 percent increase over earnings of $30.86 thousand per share from the same period last year. The company reported $29.58 million in sales this quarter. This is a 132.37 percent increase over sales of $12.73 million the same period last year.

Earnings

HPAI

Helport AI FY EPS $47.24K Up From $30.86 thousand YoY, Sales $29.58M Up From $12.73M YoY

Equillium (EQ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wain...

Buy Rating Affirmed: Equillium's EQ101 Shows Promising Results in Phase 2 Alopecia Areata Study

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Equillium (EQ – Research Report), Lexeo Therapeuti...

Analysts Conflicted on These Healthcare Names: Equillium (EQ), Lexeo Therapeutics, Inc. (LXEO) and Teladoc (TDOC)

Equillium to join Russell Microcap Index

The healthcare industry is expected to witness robust growth driven by increased demand for medicines. Therefore, small-cap Wall Street healthcare favorites Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and Equillium (EQ) might be ideal additions to your portfolio. Keep reading… The healthcare industry is poised for substantial growth thanks to rising healthcare needs, the adoption of cutting-edge technologies, and the increasing demand for generic drugs. Given the industry's bright prospects, it could be wise to invest in fundamentally strong healthcare stocks, Amphastar Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/AMPH/">AMPH</a>), Catalyst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/CPRX/">CPRX</a>), and Equillium, Inc. (<a href="https://stocknews.com/stock/EQ/">EQ</a>).
The healthcare market is set to expand significantly in the coming years, driven by factors such as the growing aging population, expanded health insurance coverage, government healthcare programs, increasing demand for generic drugs, and advancements in medical technology. In fact, the healthcare services market size is projected to grow at a <a href="https://www.researchandmarkets.com/reports/5781185/healthcare-services-global-market-report">CAGR of 5% by 2028</a>, offering a promising investment opportunity.
Moreover, the healthcare industry is on the brink of exciting innovations. With an average of <a href="https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-use-of-medicines-in-the-us-2024">50-55 new medicines expected to be launched per year</a> over the next five years and increasing R&amp;D on drug discovery, the total net spending on medicines in 2028 is projected to increase by $127 billion. This potential for innovation is a thrilling prospect for the healthcare market.
Considering these conducive trends, let's analyze the fundamentals of the three medical stock picks mentioned above. While the small market capitalization of these stocks might indicate a greater susceptibility to volatility, Wall Street analysts seem to love these.
Amphastar Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/AMPH/">AMPH</a>)
AMPH is a biopharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company has a $1.98 billion market capitalization.
On May 22, 2024, AMPH announced that the U.S. Food and Drug Administration (FDA) had granted approval for the company's Abbreviated New Drug Application for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008.
This product treats bronchospasm in patients four years of age and older with reversible obstructive airway disease and prevents exercise-induced bronchospasm in patients four years of age and older.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin, AMPH's 31.29% is considerably higher than the 1.61% industry average. Likewise, its 37.79% trailing-12-month levered FCF margin is significantly higher than the 1.21% industry average. Furthermore, its 37.87% trailing-12-month EBITDA margin is 570.5% higher than the 5.65% industry average.
AMPH's total revenues for the first quarter that ended March 31, 2024, rose 12.6% year-over-year to $171.84 million. Its gross profit increased 22% year-over-year to $90.10 million. Likewise, the company's non-GAAP net income came in at $55.30 million, or $1.04 per share, up 72.1% and 67.7% year-over-year, respectively.
Street expects AMPH's revenue and EPS for the quarter ending June 30, 2024, to increase 19.1% and 19.5% year-over-year to $173.54 million and $0.78, respectively. It surpassed the consensus EPS and revenue estimates in three of the trailing four quarters, which is impressive.
The stock has lost marginally intraday to close the last trading session at $40.49. Based on four Wall Street analysts offering 12-month price targets for AMPH in the last three months, <a href="https://www.tipranks.com/stocks/amph/forecast">the average price target is $63.67</a>, indicating a 57.2% upside, with a high forecast of $71 and a low forecast of $50.
AMPH's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
AMPH has a B grade for Growth and Value. It is ranked #23 out of 155 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry.
In addition to the POWR Ratings we've stated above, we also have AMPH ratings for Sentiment, Quality, Momentum, and Stability. Get all AMPH ratings <a href="https://stocknews.com/stock/AMPH/">here</a>.
Catalyst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/CPRX/">CPRX</a>)
With a market cap of $1.78 billion, CPRX is a commercial-stage biopharmaceutical company that focuses on developing and commercializing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases in the United States.
On May 30, 2024, CPRX announced that the FDA had approved its supplemental New Drug Application (sNDA), increasing the indicated maximum daily dose of FIRDAPSE for adults and pediatric patients for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). The increased maximum daily dose offers healthcare providers and patients greater flexibility in treatment regimens for LEMS management.
CPRX's trailing-12-month gross profit margin of 64.33% is 12.8% higher than the industry average of 57.06%. Its trailing-12-month EBITDA margin of 27.72% is 390.8% higher than the industry average of 5.65%.
For the fiscal first quarter that ended March 31, 2024, CPRX's total revenues increased 15.4% year-over-year to $98.51 million. Its operating income amounted to $27.13 million. For the same quarter, its non-GAAP net income and net income per share stood at $46.77 million and $0.38, respectively.
Analysts expect CPRX's revenue for the second quarter ending June 2024, to increase 12.4% year-over-year to $111.96 million. The company's EPS is expected to be $0.23 for the same quarter. Moreover, the company has surpassed revenue estimates in three of the trailing four quarters.
CPRX's stock has gained 27.3% over the past year to close the last trading session at $15.06.
Based on five Wall Street analysts offering 12-month price targets for CPRX in the last three months, <a href="https://www.tipranks.com/stocks/cprx/forecast">the average price target is $26.50</a>, indicating a 76% upside, with a high forecast of $29.00 and a low forecast of $24.00.
CPRX's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
The stock has a B grade for Value and Quality. CPRX is ranked #41 in the same industry.
<a href="https://stocknews.com/stock/CPRX/">Click here</a> to access all CPRX ratings (Momentum, Sentiment, Growth, and Stability).
Equillium, Inc. (<a href="https://stocknews.com/stock/EQ/">EQ</a>)
EQ is a biotech company specializing in treatments for severe autoimmune disorders. The company's lead product, itolizumab (EQ001), is in Phase III trials for acute graft-versus-host disease. It also has projects for conditions like cutaneous T-cell lymphoma and alopecia areata. The company has a market cap of $25.14 million.
On June 4, 2024, EQ announced positive topline data from its Phase 2, single-dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe, or very severe alopecia areata, which is an autoimmune disease driven by an immune cell attack of the hair follicles that causes hair loss.
EQ's trailing-12-month gross profit margin of 100% is 74.8% higher than the industry average of 57.21%. Its trailing-12-month asset turnover ratio of 0.66x is 63.4% higher than the industry average of negative 0.40x.
For the first quarter, which ended March 31, 2024, EQ's revenue increased 20.4% year-over-year to $10.69 million. As of March 31, 2024, its total liabilities amounted to $22.50 million, compared to $27.96 million as of December 31, 2023. Moreover, its cash, cash equivalents, and short-term investments amounted to $32.29 million as of March 31, 2024.
Street expects EQ's revenue for the fiscal quarter (ending September 2024) to increase 181% year-over-year to $24.93 million, and its EPS for the same period is estimated to be $0.60. Further, EQ topped the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past six months, the stock has gained 9.2% to close the last trading session at $0.71.
Based on two Wall Street analysts offering 12-month price targets for EQ in the last three months, <a href="https://www.tipranks.com/stocks/eq/forecast">the average price target is $6</a>, indicating a 741.5% upside. The high forecast is $7, and the low forecast is $5.
EQ's POWR Ratings reflect its promising outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. 
The stock has an A grade for Sentiment and a B for Value and Quality. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, EQ is ranked #23 out of 354 stocks.
<a href="https://stocknews.com/stock/EQ/">Click here</a> to access additional ratings of EQ for Stability, Growth, and Momentum.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
AMPH shares closed at $40.49 on Friday, down $-0.14 (-0.34%). Year-to-date, AMPH has declined -34.54%, versus a 14.55% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/amph-cprx-eq-3-small-cap-healthcare-stocks-wall-street-loves/>3 Small-Cap Healthcare Stocks Wall Street Loves</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Healthcare Stocks Wall Street Loves

Equillium GAAP EPS of $0.01 beats by $0.16, revenue of $13.9M beats by $7.57M

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AC Immune SA (ACIU – Research Report), Equillium (EQ...

Analysts' Top Healthcare Picks: AC Immune SA (ACIU), Equillium (EQ)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Equillium (NASDAQ:<a href="https://investorplace.com/stock-quotes/eq-stock-quote/">EQ</a>) just reported results for the second quarter of 2024.<ul><li>Equillium reported earnings per share of 1 cent. This was above the analyst estimate for EPS of -15 cents.</li><li>The company reported revenue of $13.85 million.</li><li>This was 119.02% better than the analyst estimate for revenue of $6.33 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/eq-stock-earnings-equillium-for-q2-of-2024/">EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Equillium (EQ – Research Report), Foghorn Therapeuti...

Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)

Equillium says Ono not acquiring itolizumab, stock craters 36%

JonesResearch downgraded Equillium (EQ) to Hold from Buy without a price target after the company announced that Ono Pharmaceutical (OPHLY) decline...

Comments

Equillium

Equillium (EQ) Opciones

Equillium (NASDAQ:EQ) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL